PLoS ONE (Jan 2015)

Dendritic Cells Cause Bone Lesions in a New Mouse Model of Histiocytosis.

  • Frédéric Grosjean,
  • Sonia Nasi,
  • Pascal Schneider,
  • Véronique Chobaz,
  • Alexandra Liu,
  • Vanessa Mordasini,
  • Kristell Moullec,
  • Paolo Vezzoni,
  • Christine Lavanchy,
  • Nathalie Busso,
  • Hans Acha-Orbea,
  • Driss Ehirchiou

DOI
https://doi.org/10.1371/journal.pone.0133917
Journal volume & issue
Vol. 10, no. 8
p. e0133917

Abstract

Read online

Langerhans cell histiocytosis (LCH) is a rare disease caused by the clonal accumulation of dendritic Langerhans cells, which is often accompanied by osteolytic lesions. It has been reported that osteoclast-like cells play a major role in the pathogenic bone destruction seen in patients with LCH and these cells are postulated to originate from the fusion of DCs. However, due to the lack of reliable animal models the pathogenesis of LCH is still poorly understood. In this study, we have established a mouse model of histiocytosis- recapitulating human disease for osteolytic lesions seen in LCH patients. At 12 weeks after birth, severe bone lesions were observed in our multisystem histiocytosis (Mushi) model, when CD8α conventional dendritic cells (DCs) are transformed (MuTuDC) and accumulate. Most importantly, our study demonstrates that bone loss in LCH can be accounted for the transdifferentiation of MuTuDCs into functional osteoclasts both in vivo and in vitro. Moreover, we have shown that injected MuTuDCs reverse the osteopetrotic phenotype of oc/oc mice in vivo. In conclusion, our results support a crucial role of DCs in bone lesions in histiocytosis patients. Furthermore, our new model of LCH based on adoptive transfer of MuTuDC lines, leading to bone lesions within 1-2 weeks, will be an important tool for investigating the pathophysiology of this disease and ultimately for evaluating the potential of anti-resorptive drugs for the treatment of bone lesions.